Anonymized Summary of Judgment

Factual and Procedural Background

The Plaintiff sought a Collective Proceedings Order under section 47B(4) of the Competition Act 1998 to bring opt-out collective claims against six statutory water and sewerage undertakers (hereafter "Company A" to "Company F") on behalf of consumers. The Plaintiff alleged each Company had misleadingly understated the number of pollution incidents in its area, causing the Regulatory Authority to set higher Revenue Allowances and thereby permitting higher charges to consumers. The Tribunal refused the Collective Proceedings Order on the ground that the Plaintiff's claims for abuse of a dominant position under section 18 of the Competition Act 1998 were excluded by section 18(8) of the Water Industry Act 1991. The present appeal asks whether the Tribunal was correct as a matter of law.

Legal Issues Presented

1. Whether section 18(8) of the Water Industry Act 1991 excludes the Plaintiff's Chapter II (section 18) claims that Companies A–F abused their dominant positions by misleading the Regulatory Authority about pollution incidents.
2. If section 18(8) applies, whether it only excludes remedies "for which the contravention is an essential ingredient" of the claim (as interpreted by the Supreme Court in MSC2) and whether that test is satisfied on these facts.
3. How the authorities on misleading public authorities (notably AstraZeneca), Marcic, and MSC2 should be applied to exploitative abuse claims grounded in regulatory reporting and price-control consequences.

Arguments of the Parties

Plaintiff's Arguments

• The claim is a competition law claim based on false or misleading representations to the Regulatory Authority (and to the Environmental Agency), actionable under section 18 CA 1998; any calculation of loss is an economic exercise separate from the legal characterisation of the misleading act.
• The alleged breaches of licence/reporting conditions are background/contextual facts, not essential legal ingredients; MSC2 preserves common-law remedies where the statutory contravention is not an essential ingredient.
• AstraZeneca establishes that misleading a regulator can amount to abuse; the present claim is a fact-specific abuse claim and not dependent on there being a separate statutory cause of action.

Companies' and Regulatory Respondents' Arguments

• The remedies claimed are in substance remedies "by virtue of" the act constituting a contravention of licence/appointment conditions under the Water Industry Act 1991; absent the price-control and reporting regime Companies A–F had no duty to report to the Regulatory Authority.
• The alleged misreporting can only be understood by reference to the reporting obligations (e.g. paragraph 9.2 of Condition B) and the price-control mechanism; therefore section 18(8) excludes the competition claim.
• The Regulatory Authority can address the matter under the statutory enforcement and penalty regime (and has indicated it considers enforcement orders could require reimbursement), which supports the exclusion of competition remedies in this factual context.

Table of Precedents Cited

Court's Reasoning and Analysis

The court applied MSC2's interpretative framework for section 18(8): remedies are excluded only where the contravention of the Water Industry Act 1991 (WIA) is an essential ingredient of the claim. The central analytical steps were:

1. Identify the impugned "act": the provision of inaccurate or under‑reported pollution-incident information to the Regulatory Authority (directly) and indirectly via the Environmental Agency.
2. Examine the pleaded abuse: the Plaintiff alleges exploitative abuse (charging higher prices) caused by misleading the regulator, relying principally on AstraZeneca for the proposition that misleading a regulator can be abusive, subject to factual assessment.
3. Determine whether the remedy sought is available "otherwise than by virtue of" the act constituting a contravention of licence/appointment conditions (the key statutory phrase). If the remedy depends on the act being a contravention, section 18(8) excludes it.
4. The court analysed the pleaded material and regulatory structure and concluded that Ofwat (the Regulatory Authority) relied on information supplied because the reporting obligation (Condition B, para 9.2) required accurate reporting; the alleged misleading arose by reference to what would have been reported had the duty been complied with.
5. Applying a purposive and realistic approach (endorsing Rossendale et alia), the court held that the claim cannot realistically be divorced from the statutory reporting and price-control regime: the alleged misuse was the contravention of licence conditions that fed into the price-control mechanism and allowed higher Revenue Allowances.
6. Accordingly, the court concluded the Plaintiff's remedies are claimed "by virtue of" the acts constituting contraventions of appointment/licence conditions and are therefore excluded by section 18(8). The Tribunal's conclusion was upheld, though the court explained its own reasoning differs in emphasis from the Tribunal's formulation.
7. The court addressed counter-arguments (e.g. that the claim could be pleaded as a free-standing abuse irrespective of statutory breach, and that Ofwat could have pursued competition infringements and thereby enabled follow-on claims) but found those arguments insufficient given the pleaded dependence on the reporting regime and the realistic operation of the statutory scheme.
8. The court acknowledged a vigorous dissent (Judge Zacaroli) who would have allowed the appeal on the basis that the essential ingredients of the abuse claim do not require the inaccurate reporting to be a contravention of the licence condition; the majority rejected that view.

Holding and Implications

HOLDING: The appeal is dismissed. The court concluded that section 18(8) of the Water Industry Act 1991 is engaged and excludes the Plaintiff's claimed remedies because those remedies are available only by virtue of the acts complained of constituting contraventions of conditions of appointment under the WIA.

Implications:

• Direct effect: The Plaintiff's proposed collective competition claims against Companies A–F are barred by section 18(8) insofar as the remedies sought depend on the acts constituting contraventions of licence/appointment conditions; the Collective Proceedings Order remains refused on that legal ground.
• The court emphasised that misleading a regulator can amount to abuse in principle (on AstraZeneca) but that, on these facts, the alleged misleading depended on breach of the statutory reporting and price-control regime and so fell within section 18(8)'s exclusion.
• No novel general rule expanding or contracting section 18(8) beyond the application on these facts was laid down; the decision applies MSC2 purposively to exploitative abuse claims grounded in regulatory reporting and price-control consequences.

Disposition and Separate Judgment

The majority (Judge [Master of the Rolls] and Judge Falk) dismissed the appeal for the reasons above. Judge Zacaroli dissented, concluding the essential ingredients of the Plaintiff's abuse claim do not require that the inaccurate reporting be a contravention of the licence conditions and would have allowed the appeal.

This summary is strictly confined to the information contained in the provided opinion and anonymizes parties and non-case-name entities in accordance with the instructions.